Business
M2Bio-Discovery Centre for AI-Driven Phytomedicine Research: Update
M2Bio-Discovery Centre for AI-Driven Phytomedicine Research: Update.
About this update from Institute Of Biomedical Research Corp.
[{"type":"text","content":"CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / September 13, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to present a groundbreaking update on its latest scientific endeavor: M2Bio Sciences endeavors to usher in a paradigm shift within the realm of medical health by focusing on the foundational facet of drug discovery. Historically, pharmaceutical development has been indispensable in addressing various medical conditions, from combating bacterial pathogens to mitigating cardiovascular diseases. However, the drug discovery process has been characterized by exorbitant costs, protracted timelines, and ethical considerations involving animal and human trials. In light of the maturation of artificial intelligence, particularly in the domain of general AI, M2Bio posits that this process can be substantially expedited and rendered more cost-effective, with minimal ethical implications, through the utilization of machine learning (ML) models and mature general AI algorithms.M2Bio Sciences has appointed Ze-ev Krein, an interdisciplinary scientist, and M2Bio Scientific Advisory Board Chairman, to spearhead this pioneering research initiative. Mr. Krein possesses a unique blend of expertise encompassing drug discovery, computer science, and legal background, which includes familiarity with compliance and the legal intricacies associated with drug research and discovery.Krein, under the tutelage of Prof. Maharaj at the University of Pretoria, will conduct research that contributes both to M2Bio's drug discovery program and to his doctorate, focusing on the most advanced applications of AI in drug discovery. M2Bio will retain the intellectual property and commercial rights for the lead compounds, while the center will actively collaborate with numerous institutions and researchers to foster progress through open-source and joint venture collaborations. Updates on research progress will be periodically disseminated through M2Bio's various media channels.M2Bio Sciences continues to make substantial investments in AI, which constitutes a fundamental pillar of the company's holistic health appr...